α-Mercaptoketone based histone deacetylase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 24, 2008, Pages 6482-6485

  Wash, Paul L ^a   Hoffman, Timothy Z ^a   Wiley, Brandon M ^a   Bonnefous, Céline ^a   Smith, Nicholas D ^a   Sertic, Michael S ^a   Lawrence, Charles M ^a   Symons, Kent T ^a   Nguyen, Phan Manh ^a   Lustig, Kevin D ^a   Guo, Xin ^a   Annable, Tami ^a   Noble, Stewart A ^a   Hager, Jeffrey H ^a   Hassig, Christian A ^a   Malecha, James W ^a  

^a Kalypsys Inc   (United States)

Author keywords

Anti tumor agent; Histone deacetylase inhibitor; Mercaptoketone; Prodrug; SAR

Indexed keywords

ALPHA MERCAPTOKETONE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; KETONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; HELA CELL; HUMAN; HUMAN CELL; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CHELATING AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HELA CELLS; HISTONE DEACETYLASES; HUMANS; KETONES; MODELS, CHEMICAL; NEOPLASMS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC;

EID: 56249122313     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.10.058     Document Type: Article

References (14)

1. Paris G., Porcelloni M., Binaschi M., and Fattori D. J. Med. Chem. 51 (2008) 1505
2. Marks P.A. Oncogene 26 (2007) 1351
3. Vassiliou S., Mucha A., Cuniasse P., Georgiadis D., Lucet-Levannier K., Beau F., Kannan R., Murphy G., Knaeuper V., Rio M.C., Basset P., Yiotakis A., and Dive V. J. Med. Chem. 42 (1999) 2610
4. Suzuki T., and Miyata N. Curr. Med. Chem. 12 (2005) 2867
5. Hassig C.A., Symons K.T., Guo X., Nguyen P., Annable T., Wash P.L., Payne J.E., Jenkins D.A., Bonnefous C., Trotter C., Wang Y., Anzola J.V., Milkova E.L., Hoffman T.Z., Dozier S.J., Wiley B.M., Saven A., Malecha J.W., Davis R.L., Shiau A.K., Noble S.A., Rao T.S., Smith N.D., and Hager J.H. Mol. Cancer Ther. 7 (2008) 1054
6. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., and Horinouchi S. Cancer Res. 62 (2002) 4916
7. Vanommeslaeghe K., Loverix S., Geerlings P., and Tourwe D. Bioorg. Med. Chem. 13 (2005) 6070
8. Gu W., Nusinzon I., Smith R.D., Horvath C.M., and Silverman R.B. Bioorg. Med. Chem. 14 (2006) 3320
9. Suzuki T., Matsuura A., Kouketsu A., Nakagawa H.M., and Miyata N. Bioorg. Med. Chem. Lett. 15 (2005) 331
10. Chen B., Petukhov P.A., Jung M., Velena A., Eliseeva E., Dritschilo A., and Kozikowski A.P. Bioorg. Med. Chem. Lett. 15 (2005) 1389
11. Anandan S.K., Ward J.S., Brokx R.D., Bray M.R., Patel D.V., and Xiao X.X. Bioorg. Med. Chem. Lett. 15 (2005) 1969
12. Additional efforts at improving the aqueous solubility in the series are detailed in the following paper: Smith, N. D. et al., Bioorg. Med. Chem. Lett.
13. T/C: (treated final volume - treated initial volume)/(control final volume - control initial volume) × 100. A T/C value of 0 equals tumor stasis.
14. Feng R., Ma H., Hassig C.A., Payne J.E., Smith N.D., Mapara M.Y., Hager J.H., and Lentzsch S. Mol. Cancer Ther. 7 (2008) 1494